[go: up one dir, main page]

CO4810374A1 - NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY - Google Patents

NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Info

Publication number
CO4810374A1
CO4810374A1 CO98060225A CO98060225A CO4810374A1 CO 4810374 A1 CO4810374 A1 CO 4810374A1 CO 98060225 A CO98060225 A CO 98060225A CO 98060225 A CO98060225 A CO 98060225A CO 4810374 A1 CO4810374 A1 CO 4810374A1
Authority
CO
Colombia
Prior art keywords
compounds
mammal
independently
compound
case
Prior art date
Application number
CO98060225A
Other languages
Spanish (es)
Inventor
Don E Griswold
Iv Siegfried B Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4810374A1 publication Critical patent/CO4810374A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método de tratamiento de prurito en un mamífero que necesitade ello, que comprende administrar a dicho mamífero una cantidad eficaz de un compuesto de un inhibidor de PDE4 , distinto de CP 80633. El método según la reivindicación 1, en el que el inhibidor de PDE4 es un compuesto de la fórmula: en la que: R1 y R2 , independientemente en cada caso, representan alquilo o -(CH2 )m -A; m representa cero o el número entero 1, 2 ó 3; A representa un radical hidrocarbonado cíclico no sustituido o sustituido; R3 representa un átomo de halógeno, un grupo nitro o un grupo -NR4 R5 ; R4 y R5 , independientemente en cada caso, representan hidrógeno, alquilo o alquilcarbonilo, o R4 y R5 junto con el nitrógeno al que están unidos forman un anillo heterocíclico opcionalmente sustituido; y sus sales farmacéuticamente aceptables.A method of treating pruritus in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633. The method according to claim 1, wherein the PDE4 inhibitor it is a compound of the formula: wherein: R1 and R2, independently in each case, represent alkyl or - (CH2) m -A; m represents zero or the integer 1, 2 or 3; A represents an unsubstituted or substituted cyclic hydrocarbon radical; R3 represents a halogen atom, a nitro group or a -NR4 R5 group; R4 and R5, independently in each case, represent hydrogen, alkyl or alkylcarbonyl, or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; and its pharmaceutically acceptable salts.

CO98060225A 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY CO4810374A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17

Publications (1)

Publication Number Publication Date
CO4810374A1 true CO4810374A1 (en) 1999-06-30

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98060225A CO4810374A1 (en) 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Country Status (18)

Country Link
EP (1) EP1030666A4 (en)
JP (1) JP2001520196A (en)
KR (1) KR20010031149A (en)
CN (1) CN1306426A (en)
AR (1) AR015966A1 (en)
AU (1) AU740875B2 (en)
BR (1) BR9814080A (en)
CA (1) CA2306985A1 (en)
CO (1) CO4810374A1 (en)
CZ (1) CZ20001376A3 (en)
HU (1) HUP0003792A3 (en)
IL (1) IL135581A0 (en)
NO (1) NO20001847D0 (en)
NZ (1) NZ503551A (en)
PL (1) PL341062A1 (en)
TR (1) TR200001040T2 (en)
WO (1) WO1999020280A1 (en)
ZA (1) ZA989450B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
CA2436551A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
PL364135A1 (en) 2001-01-31 2004-12-13 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
US20060258703A1 (en) * 2003-07-17 2006-11-16 Ono Pharmaceutical Co., Ltd. Remedy for pruritus comprising piperidine derivative as the active ingredient
JP2005187458A (en) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd Itchiness-treating agent consisting of cilomilast or its salt as active ingredient
WO2005053672A1 (en) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
CN101103030B (en) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 Medicaments with HM74A receptor activity
JP2008137892A (en) * 2005-03-04 2008-06-19 Eisai Co Ltd Antipruritic agent
JP2009504592A (en) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション Xanthine derivatives as selective HM74A agonists
EP1992622B1 (en) * 2006-02-21 2011-07-27 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
TWI404709B (en) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
WO2008099887A1 (en) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
CA2696727A1 (en) 2007-08-17 2009-02-26 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
AU2008290001B2 (en) 2007-08-17 2012-08-09 Eisai R & D Management Co., Ltd. Novel preparation for external use
WO2013002196A1 (en) 2011-06-28 2013-01-03 田辺三菱製薬株式会社 Novel pharmaceutical composition
SI3251675T1 (en) 2015-01-30 2021-08-31 Shanton Pharma Pte. Ltd. Prevention or treatment of uric acid or gout disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011260A1 (en) * 1990-12-21 1992-07-09 Beecham Group Plc Xanthine derivatives
EP0889886B1 (en) * 1996-03-26 2002-09-18 ALTANA Pharma AG Novel phenanthridines substituted in the 6 position
JP2000510134A (en) * 1996-05-15 2000-08-08 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング New imidazopyridine
JP2001514640A (en) * 1997-03-07 2001-09-11 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング New tetrazole
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
DE69811492T2 (en) * 1997-06-03 2004-02-05 Altana Pharma Ag BENZONAPHTHYRIDINE

Also Published As

Publication number Publication date
CA2306985A1 (en) 1999-04-29
EP1030666A1 (en) 2000-08-30
HUP0003792A3 (en) 2001-12-28
CZ20001376A3 (en) 2002-06-12
IL135581A0 (en) 2001-05-20
AU740875B2 (en) 2001-11-15
NZ503551A (en) 2002-05-31
BR9814080A (en) 2000-09-26
EP1030666A4 (en) 2002-10-16
AR015966A1 (en) 2001-05-30
TR200001040T2 (en) 2001-01-22
HUP0003792A2 (en) 2001-10-28
CN1306426A (en) 2001-08-01
NO20001847L (en) 2000-04-10
AU1093899A (en) 1999-05-10
ZA989450B (en) 1999-04-19
NO20001847D0 (en) 2000-04-10
KR20010031149A (en) 2001-04-16
JP2001520196A (en) 2001-10-30
WO1999020280A1 (en) 1999-04-29
PL341062A1 (en) 2001-03-26

Similar Documents

Publication Publication Date Title
CO4810374A1 (en) NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY
AR044719A1 (en) DERIVATIVES OF PHENYL AND PIRIDINYL, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
CO5140087A1 (en) DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM
AR010331A1 (en) COMPOUNDS DERIVED FROM 6-PHENYLPYRIDYL-2-AMINE USEFUL AS INHIBITORS US, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS OF TREATMENT USING THESE COMPOUNDS.
AR029614A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR002746A1 (en) PIRIMIDINE-DERIVED COMPOUNDS CONDENSED WITH A HETERO-CYCLIC RING AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS.
ECSP088550A (en) NEW COMPOUNDS THAT ARE ERK INHIBITORS
AR035548A1 (en) ORGANIC COMPOUNDS
CO5060482A1 (en) BIARILO THERAPEUTIC DERIVATIVES
DE69310501D1 (en) CHINOLYLBENZOFURAN DERIVATIVES AS LEUKOTRIA ANTAGONISTS
ES2039242T3 (en) A PROCEDURE FOR THE PREPARATION OF NEW PIPERIDINE DERIVATIVES.
CO5160347A1 (en) CARBAMIC ACID DERIVATIVES
ATE280763T1 (en) MATRIX METALLOPROTEINASE INHIBITORS
ES2123652T3 (en) 7- (2-AMINOETIL) -BENZOTIAZOLONAS.
ATE120955T1 (en) BENZYLIDENE-MALONONITRILE DERIVATIVES FOR INHIBITING PROLIFERATIVE PROCESSES IN MAMMAL CELLS.
CO4950553A1 (en) 7-TETRAHYDROISOKINOLIN COMPOUNDS AND PROCEDURE FOR THE PREPARATION
AR003469A1 (en) 2- (4-SUBSTITUTED) -BENCILAMINO-2-METHYL-PROPANAMIDES, ITS USE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR012603A1 (en) PROTEASE INHIBITOR, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT; AND SYNTHESIS INTERMEDIARIES
PE20011134A1 (en) 4-FLUORALKYL-2H-BENZOPYRANES WITH ANTIESTROGENIC EFFECT, METHOD FOR OBTAINING THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM AND THEIR USE TO OBTAIN MEDICINES
AR016644A1 (en) COMPOUNDS OF 2-AMINOPIRIDINAS WITH ALCOXI RAMIFIED SUBSTITUTES, PHARMACEUTICAL COMPOSITION AND USE FOR THE MANUFACTURE OF MEDICINES
NO964698D0 (en) Bicyclic amine derivatives as inhibitors of nitric oxide synthetase
MX9400253A (en) DERIVATIVES OF PIPERAZINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2077998T3 (en) DERIVATIVES OF 2-AMINOPYRIMIDINE-4-CARBOXAMIDE, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION.
CO5160261A1 (en) SUBSTITUTED BIFENYL DERIVATIVES THAT ARE NK-1 ANTAGONISTS, THEIR SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ332030A (en) Sulfonamide substituted chromans, processes for their preparation, their use as a medicament and pharmaceutical preparations comprising them